factor Xa


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to factor Xa: factor IIa

factor Xa

a serine endopeptidase that catalyzes the conversion of prothrombin to active thrombin.

fac·tor Xa

(fak'tŏr)
The active form of factor X; it is formed from factor X by limited proteolysis via factor VIIa and tissue factor (extrinsic pathway) or factor IXa, VIIIa (intrinsic pathway). Factor Xa forms a complex with factor Va, phospholipid, and calcium to convert prothrombin to thrombin.
References in periodicals archive ?
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
The dPT ratio showed a linear increase in relation to increasing anti-Xa values in all samples spiked with factor Xa inhibitors (1:500 dilution of thromboplastin reagent, danaparoid [Figure 4, A], r = 0.
2] Nonstandard abbreviations: DTI, direct thrombin inhibitor; DFXaI, direct factor Xa inhibitor; PT, prothrombin time; APTT, activated partial thromboplastin time.
Specifically, it is a measure of the body's inhibition of factor Xa.
Major bleeding events occur infrequently in patients taking Factor Xa inhibitors (1-4% per year in clinical studies) and standard measures are employed to manage these events.
Betrixaban represents an important addition to our late-stage portfolio with the potential to be a significant medicine in the Factor Xa inhibitor class," said Luciano Rossetti M.
Within two minutes following completion of the 210 mg and 420 mg bolus of andexanet alfa, anti Factor Xa activity decreased dose-dependently by 20 percent and 53 percent respectively.
The Competitive Intelligence Report Antithrombotics as of May 2007 provides a competitor analysis in the development pipeline of novel anticoagulant and antiplatelet agents directed against targets such as factor IIa (thrombin), factor Xa, the ADP platelet receptor and PAR-1 /thrombin receptor and other novel targets.
Rivaroxaban is an oral anticoagulant, direct factor Xa inhibitor, developed by Bayer HealthCare and sold under the trademark Xarelto.
San Francisco / USA, to evaluate the safety of PRT4445, an investigational antidote for Factor Xa inhibitors, in healthy volunteers who have been administered the oral anticoagulant XareltoA (rivaroxaban).
Rivaroxaban is a novel, oral, once-daily direct Factor Xa inhibitor in advanced clinical development for a range of patients who could benefit from the prevention and/or treatment of blood clots.
The oral direct Factor Xa inhibitor proved decrease in risks compared to warfarin in three major results of stroke, major bleeding and all-cause death.